NASDAQ:ZYNE Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis → My top 100 stocks… (From DTI) (Ad) Free ZYNE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.26▼$1.3450-Day Range$1.21▼$1.3952-Week Range$0.25▼$1.40Volume862,700 shsAverage Volume515,333 shsMarket Capitalization$70.12 millionP/E RatioN/ADividend YieldN/APrice Target$1.11 Stock AnalysisStock Analysis Get Zynerba Pharmaceuticals alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.Read More Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide ZYNE Stock News HeadlinesOctober 31, 2023 | finance.yahoo.comHarmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsOctober 13, 2023 | fool.comWhy Shares of Harmony Bioscience Are Falling on FridayApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.October 11, 2023 | markets.businessinsider.comNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesOctober 11, 2023 | finance.yahoo.comHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEOctober 4, 2023 | finance.yahoo.comImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsSeptember 29, 2023 | finance.yahoo.com20 Countries With Highest Rate of EpilepsySeptember 29, 2023 | finance.yahoo.comZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023April 27, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… September 27, 2023 | bizjournals.comHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealSeptember 14, 2023 | finance.yahoo.comInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncSeptember 14, 2023 | finance.yahoo.comZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumAugust 16, 2023 | msn.comHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)August 15, 2023 | finance.yahoo.comIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?August 14, 2023 | marketwatch.comZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEAugust 14, 2023 | markets.businessinsider.comCrude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike HigherAugust 14, 2023 | technews.tmcnet.comZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 14, 2023 | finance.yahoo.comHARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.July 25, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces New Date for Reconvened Annual MeetingJune 29, 2023 | finance.yahoo.comZynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?June 28, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Further Adjournment of Annual MeetingJune 20, 2023 | finance.yahoo.comZynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferenceJune 13, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Partial Adjournment of Annual MeetingMay 17, 2023 | bizjournals.comMain Line CBD drug developer plans reverse stock split to boost share priceMay 15, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsMay 15, 2023 | investing.comZynerba Pharma (ZYNE) Earnings Dates & ReportsMay 15, 2023 | msn.comZynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The DetailsSee More Headlines Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZYNE CUSIPN/A CIK1621443 Webwww.zynerba.com Phone(484) 581-7505FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$1.11 High Stock Price Target$1.11 Low Stock Price Target$1.11 Potential Upside/Downside-14.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.03% Return on Assets-72.62% Debt Debt-to-Equity RatioN/A Current Ratio3.43 Quick Ratio3.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book1.29Miscellaneous Outstanding Shares53,939,000Free Float46,905,000Market Cap$70.12 million OptionableOptionable Beta1.32 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Armando Anido MBA (Age 65)Chairman & CEO Comp: $934.53kMs. Terri B. Sebree (Age 65)Pres Comp: $729.15kMr. James E. Fickenscher (Age 59)CFO & VP of Corp. Devel. (Leave of Absence) Comp: $607.62kMr. Kenneth T. Jones (Age 59)VP, Corp. Controller & Interim CFO Mr. Albert P. Parker II (Age 57)Chief Legal Officer & Corp. Sec. Mr. Joseph ApostolicoVP of HRMore ExecutivesKey CompetitorsJourney MedicalNASDAQ:DERMCarisma TherapeuticsNASDAQ:CARMAnebulo PharmaceuticalsNASDAQ:ANEBLandos BiopharmaNASDAQ:LABPAssembly BiosciencesNASDAQ:ASMBView All CompetitorsInsidersArmando AnidoSold 17,830 sharesTotal: $23,713.90 ($1.33/share)Terri B SebreeSold 12,401 sharesTotal: $16,493.33 ($1.33/share)James E FickenscherSold 8,998 sharesTotal: $11,967.34 ($1.33/share)Brian RosenbergerSold 6,411 sharesTotal: $8,526.63 ($1.33/share)Kenneth T JonesSold 2,505 sharesTotal: $3,331.65 ($1.33/share) ZYNE Stock Analysis - Frequently Asked Questions Should I buy or sell Zynerba Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares. View ZYNE analyst ratings or view top-rated stocks. What is Zynerba Pharmaceuticals' stock price target for 2024? 3 Wall Street research analysts have issued 1 year target prices for Zynerba Pharmaceuticals' shares. Their ZYNE share price targets range from $1.11 to $1.11. On average, they expect the company's stock price to reach $1.11 in the next twelve months. This suggests that the stock has a possible downside of 14.6%. View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts. How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU). When did Zynerba Pharmaceuticals IPO? Zynerba Pharmaceuticals (ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. This page (NASDAQ:ZYNE) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
